期刊文献+

Avastin抑制兔角膜新生血管的实验研究 被引量:1

Inhibition of corneal neovascularization by Avastin in rabbits
原文传递
导出
摘要 目的探讨Avastin对角膜新生血管(NV)的抑制作用。方法日本大耳白兔20只,以角膜缝线法制作角膜新生血管模型,观察4周。在角膜缝线1周后,实验组以浓度为4mg/mL的Avastin溶液滴眼,对照组以注射用水滴眼,均为每日2次,共28d。记录角膜新生血管出现的时间、生长的长度和数量。结果两组角膜新生血管的出现时间分别为(3.43±0.53)d和(3.14±0.69)d(P〉0.05);在缝线后14d、21d、28d,实验组角膜新生血管的面积均明显小于对照组(P〈0.05)。且实验组角膜新生血管在用药后明显变细。两组角膜荧光素染色在观察期间均未发现明显着色。结论Avastin滴眼能够有效抑制角膜新生血管的生长,并能在一定程度上使已有的新生血管消退,且未发现明显的毒副作用。 Objective To evaluate the effect of Aavastin to inhibit experimental corneal neovascularization. Methods Twenty rabbits were sutured on the superior cornea. Animals were randomly divided into 2 groups. After 7 days, 10 eyes in the treatment group were given Aavastin drops(4 rog/mi) twice daily, whereas 10 eyes in the control group received placebo ( normal saline drops twice daily). The occurrence and developement of CNV was observed on the 3,7, 14, 21,28 days after suturing by slit-lamp microscope, and the area of CNV was calculated. Fluorescein staining was detected for the integrity of corneal epithelium. Results The occurrence of CNV in group 1 was ( 3.43 ± 0.53 ) d and group 2 ( 3.14 ±0.69 ) d. No significant difference in the occurrence time of CNV was found between group 1 and group 2. The CNV areas of group 1 were significantly smaller than that of group 2 at every time poin ( P 〈 0.05 ). The diameter of CNV was significantly smaller after Avastin treatment. Conclusion Avastin can inhibit and restrain corneal neovascularization at some degree without significant side effects.
出处 《中华眼外伤职业眼病杂志》 2011年第5期321-323,共3页 Chinese Journal of Ocular Trauma and Occupational Eye Disease
关键词 AVASTIN 角膜血管新生 Avastin corneal neovascularization rabbit
  • 相关文献

同被引文献29

  • 1冯怡,冯玉梅,朱旭东,马清钧.重组人内皮抑素滴眼液抑制小鼠角膜新生血管形成的研究[J].眼科研究,2005,23(1):12-15. 被引量:9
  • 2唐维强,柳林,刘智勇,仲明,李静,温新富.卡托普利对大鼠角膜新生血管生长的影响[J].眼科研究,2005,23(1):16-19. 被引量:7
  • 3刘勇,王恩普,李丹,刘兵,耿惠,孙永华.人Kringle1-5蛋白滴眼液抑制兔角膜新生血管的研究[J].国际眼科杂志,2006,6(2):332-336. 被引量:4
  • 4周兰新,李立,鄢秀菊.奥曲肽抑制角膜新生血管形成的实验研究[J].眼科新进展,2006,26(9):674-677. 被引量:11
  • 5Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization [J]. Curr Opin Ophthalmol,2001,12(4) :242-249.
  • 6Brogi E, Wu T, Namiki A, et al. Indirect angiogenic cytokines upregulate VEGF and BFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only [ J 1. Circulation, 1994,90 ( 2 ) :649-652.
  • 7Presta LG,Chen H, O'Connor SJ, et al. Humanization of an anti- vascularer endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer Res, 1997, 57(20) :4593-4599.
  • 8Rosenfeld PJ,Schwartz SD, Blumenkranz MS,et al. Maximum toler- ated dose of a humanized anti-vascular endothelial growth factor antibobody fragment for treating neovascular age-related macular degeneration [ J ]. Ophthlmology,2005., 112 ( 6 ) : 1048-1053.
  • 9Shukla D, Namperumalsamy P, Goldbaom M, et al. Pegaptanib sodium for ocular vascular disease[ J]. Indian J Ophthalmo1,2007, 55(6) :427..430.
  • 10葛红岩,肖楠,田霈,等.改良内皮抑素基因对大鼠角膜新生血管中血管内皮生长因子及其受体表达的抑制作用[J].中华文验眼科杂志,2012,30(1):20-24.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部